stock regain ground lost earli januari manag discuss
potenti impact propos tax rule fiscal ep well modest
headwind cvg busi face consensu estim account
issu think setup reason in-lin show
suffici reiter outperform price target
recent cvg comment sale forecast pare appropri level
believ investor expect post sale midpoint compani
guidanc organ growth time releas novemb
guid organ sale growth diabet growth high singl
digit mitg rtg growth around cvg growth approxim
time manag indic comfort upper end
rang despit year-over-year comp face cc basi tie
toughest comp fiscal equal tough comp
confer earli januari compani dial back cvg growth guidanc
said guidanc middl rang probabl
top-of-the-rang guidanc previous felt attain anticip strength
mitg rtg larg off-set pressur cvg also opinion
cvg issu may overst conservat instanc
paclitaxel concern compani cite mute effect sale view
other alreadi offer compel data contradict neg find
meta-analysi rais question paclitaxel long-term safeti note
consensu sale forecast declin nearli sinc earli januari
reflect growth close midpoint manag organ sale growth
guidanc consid appropri level revenu estim
slightli street project vs believ compani
like post sale near consensu assumpt sale forecast repres
organ growth estim street sale consensu reflect closer
organ growth slightli midpoint guidanc complet estim
shown figur page
revis ep estim fiscal alreadi reflect mdt latest tax commentari
recent lower fiscal ep forecast around
time street ep project fiscal fell chang
made respons manag discuss new tax propos could neg
affect ous-domicil compani like importantli still propos
stage outlin tax setup could chang favor would provid upsid
guidanc current estim therefor believ adjust made respons
compani comment like bake near-worst-cas scenario also
approxim basi point impact outlin tax propos
includ possibl offset addit oper expens save interest-lin leverag
acceler share repurchas still forecast close earn growth fiscal
bp earn growth rate project fiscal
larg line lrp target addit despit tax-specif issu
compani flag confid abil deliv organ revenu
growth bp annual underli oper margin improv compani
also convict free cash flow gener hit lrp target
convers ratio within next year
pleas see page report import disclosur
outperform rate driven optimist outlook
sustain mid-single-digit top-lin growth trajectori combin mdt/cov
entiti combin cost synergi tax rate improv expect
new meet/exce goal grow adjust ep faster
revenu expect pipelin growth driver like becom focu investor
product contribut meaning first full year commerci
view new continu top-tier top- bottom-lin growth
perform medic devic space
on-going launch new product
resolut onyx
maintain de market share
us
stabil us spine
strong adopt corevalv us
return growth spine franchis
out-year top-lin growth acceler
market share loss
continu deterior spine
weak adopt trend new product
diversifi medic technolog servic solut compani presenc
countri combin entiti covidien
merger new oper four segment cardiac vascular group
minim invas therapi group diabet restor therapi group cardiac
vascular group segment manufactur market device-bas medic therapi
cardiac rhythm heart failur crhf coronari structur heart aortic
peripher vascular mitg focus advanc gener surgic technolog
diabet segment manufactur market device-bas medic therapi diabet
restor therapi group segment manufactur market device-bas medic
therapi spine neuromodul surgic technolog
momentum emerg market
cvg sale forecast adjust
strong despit tougher comp
emerg market growth standout past quarter
final two quarter fiscal
respect emerg market repres mdt total revenu compani
experienc strong growth rate multipl geographi prior quarter growth
china growth eastern europ growth middl east africa
comp get bp easier sequenti basi optimist
deliv low teen cc sale growth diabet also area
strength compani divis grew sale growth
slow difficult comparison rel howev
sale growth guidanc still high singl digit full-year fiscal guidanc
diabet sale growth low mid-teen reflect deceler compar
begin lap year-ago period regain cgm
capac also lap two key compon anima opportun consum
patient whose warranti alreadi expir nonetheless think diabet still
solid perform head launch advanc hybrid closed-loop system
fiscal forecast cc sale growth nearli line
street project year model cc growth impli cc growth
mdt cvg unit face constant currenc growth comparison rank
toughest comp fiscal coronari structur heart unit goe
hardest comparison year aortic peripher unit goe
comp tie year difficult comp cardiac rhythm heart failur
howev face second-easiest comp year wake compani
comment cvg earli januari lower cc growth assumpt
less manag guidanc sale estim
slightli street consensu howev believ sale project
mdt revis guidanc conserv view street expect
achiev specif continu think fda letter distribut mid-januari
along recent jaha meta-analysi prompt meaning affect sale
paclitaxel devic manufactur base view partli compel
data-driven counterpoint expect month ahead manufactur
first respond five-year data releas late last month also
believ second headwind cite pressur mechan support busi
part earlier-than-anticip approv abt heartmat long-term
support may overst well calcul fairli limit impact
context sale result cvg total cvg tradit end market grow
around blend basi annual optimist bounc back
follow especi given compani exposur higher-grow area like tavr
atrial fibril
rtg face second-most-difficult comparison year constant
currenc expect grow organ sale around base manag
guidanc rtg franchis come string impress quarter includ
cc growth last quarter growth growth model
cc sale growth help mazor sale forecast match street
consensu expect pain therapi post cc growth reflect compani
lap anniversari intelli launch late septemb howev
note growth assumpt compar growth rate
comp-adjust basi believ pain therapi includ target drug
deliveri pump like synchrom ii intervent devic continu grow
low teen normal basi next sever year model slightli
lower rate growth compani forecast repres upsid estim
brain therapi project cc growth compar
growth rate may conserv given easier comp rel mdt brain
portfolio encompass wide array product includ enabl technolog like mazor
 compani focus protect market share revamp current portfolio
simultan advanc pipelin brain modul recent launch
new clinician programm improv interfac also develop next-gener
primari cell devic sensing-en schedul launch fiscal
follow sensing-en direct lead fiscal addit recent
expand db epilepsi see indic growth opportun
never access specialti therapi sale growth forecast
cc bp sequenti comp-adjust basi
achiev lastli spine busi benefit stabil trend
spine market rel last year comp well continu success
surgic synergi strategi core spine plu enabl technolog said
mazor stealth edit system adopt enthusiast boost
spinal implant sale given account pay capit equip volum
commit implant
sale estim mitg match street forecast
project assum constant currenc sale growth repres
bp acceler sequenti comp-adjust basi manag guidanc
organ growth mitg view forecast like conserv look
subgroup anticip cc growth surgic innov comp
ligasur vessel-s instrument signia power surgic stapler continu
drive growth categori respiratori gi renal comp repres
toughest comp face year believ cc growth assumpt appropri
account dynam note advers effect trade china would
felt primarili mitg rtg divis manufactur export
china franchis expect issu
maintain conserv forecast nonetheless lastli respect pipelin mitg
launch updat sonicis ultrason dissect platform
soon benefit roll-out next-gener consum capnostream
respiratori monitor howev investor remain focus mdt launch robotic-
assist surgeri platform one biggest project slate launch
see numer product driver begin make impact prior
end fiscal includ low-risk tavr surgic robot platform
advanc hybrid closed-loop system diabet along regular cadenc portfolio
enhanc fiscal earn estim adjust potenti
impact current tax propos think in-lin perform suffici
reviv interest compani outlook next year reiter outperform
recommend price target deriv multipl appli
fiscal ep ebitda forecast respect multipl close
current mean multipl large-cap peer view appropri
mitg face toughest comp year
in-lin result
fiscal
cowen compani thomson eikon cowen compani
mm exclud constant currenc revenu organ constant currenc revenu good interest expens share quartercowen estimatesconsensusprior year cowen
compani report thomson eikon cowen compani
compani report thomson eikon cowen compani
medtron incom statement mm except per share y/i y/i cc good incom tax net dilut share y/i y/i y/i cowen
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
continu util pressur account organ play bigger
role health care deliveri competit dynam global potenti regulatori delay
reject failur devic clinic trial econom sensit price pressur
and/or weaken consum demand develop market econom and/or polit
uncertainti emerg market intellectu properti challeng
continu util pressur competit dynam global potenti
regulatori delay reject failur devic clinic trial econom sensit
price pressur and/or weaken demand develop market econom and/or
polit uncertainti emerg market electrophysiolog clinic commun deem
st jude medic durata lead safe effect yale independ review infus
biolog cite cancer promot effect fluctuat foreign exchang rate
